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Introduction
TRAPS is a rare autosomal dominant disease. The long
term outcome in adults has been relatively little studied.
Objectives
We describe a cohort of 80 patients with sequence variants
in TNFRSF1A who attended our centre for diagnosis and
management.
Methods
We examined medical and laboratory records for investi-
gation and test results including genotype, phenotype,
treatments and treatment responses, and organ function.
Results
Between 2000 and 2012, 80 individuals with sequence
variants and clinical disease were identified: 26 (33%)
with one of the pathogenic variants of undetermined
significance, R92Q or P46L; and 54 (67%) with one of a
variety of other known or novel pathogenic variants. 32
(40%) were male, and 42 (53%) had a positive family
history.
Of the 54 patients with a pathogenic sequence variant,
21 (39%) were not on long term treatment: 15 did not
have persistent symptoms and so were treated with inter-
mittent steroids (5 with intronic/splice junction mutations,
2 C33Y, and 1 each having H66L, D12E, C55Y, H22R,
C43G, V83M, C88Y, C96Y); 1 patient (T50M) was refrac-
tory or intolerant of other treatments; 5 patients elected
not to have treatment (1 each with C29F, C33Y, H22Q,
D42del, T50M).
33 (61%) patients were on long term treatment for
persistent and/or disabling disease symptoms: 29 (88%)
on anti-IL-1 agents, 3 (9%) on anti-TNF and 1 (3%) on
daily steroid therapy. 19 were treated with anakinra (4
C33Y, 3 T50M, 2 H22R and D42del, and 1 each of R92P,
I57S, C55Y, H22Q, C30Y, T37I, F60L, and 1 with a novel
in-frame deletion of 24 nucleotides [c.255_278del] in
exon 3); all but 1 experienced a complete remission (CR)
of disease. 10 patients were treated with canakinumab
(2 C33Y, 2 T50M, and 1 each with C30R, Y38S, C43G,
D42del, T37I, F60L); 9 have had a CR and 1 patient was
not evaluable. 3 were treated with etanercept, 1 (C33Y)
with CR and 2 (1 with T50M and the other with intronic
substitution c.626-32G>T in intron 6) having intermit-
tent steroids as well with only partial remission (PR,
defined as good but incomplete resolution of symptoms
or serum inflammatory markers). 1 patient (C33Y) with
severe disease proving refractory to other therapies was
treated with steroids 30mg daily, achieving PR.
Health-related quality of life (QoL) was surveyed in 29
patients with a pathogenic sequence variant, 10 who were
treated only with intermittent steroids as their phenotype
was not severe enough to warrant use of biologics, and 8
were surveyed before and after commencement of bio-
logic therapy. In the latter group, post-treatment scores
in physical, role and social functioning and bodily pain,
general health and vitality were all greatly improved from
prior to treatment. Interestingly, those who were only
treated with intermittent steroids showed scores compar-
able with the post-treatment scores of the group treated
with biologics, showing the impact of the untreated,
more severe phenotype on QoL.
Conclusion
This cohort shows the great variability in genotype
and phenotype associated with sequence variants in
TNFRSF1A. Those with a less severe phenotype may enjoy
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